Analysis of platelet function and dysfunction

Hamostaseologie

Volumn 35, Issue 1, 2015, Pages 60-72

  Jurk, Kerstin ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Platelet function; Platelet pathology; Platelet physiology; Point of care testing; Proteomics; Thrombin

Indexed keywords

BLOOD CLOTTING; BLOOD CLOTTING PARAMETERS; BLOOD VESSEL WALL; CLINICAL PRACTICE; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; HEMOSTASIS; HUMAN; PLASMA FACTOR; PROTEIN PROCESSING; REVIEW; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION; THROMBOCYTE FUNCTION ANALYZER; THROMBOCYTE RELEASE REACTION; BLOOD; BLOOD PLATELET DISORDERS; HOSPITAL INFORMATION SYSTEM; METABOLISM; PATHOPHYSIOLOGY; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

BLOOD PLATELET DISORDERS; BLOOD PLATELETS; HUMANS; PLATELET FUNCTION TESTS; POINT-OF-CARE SYSTEMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84939520249     PISSN: 07209355     EISSN: 25675761     Source Type: Journal    
DOI: 10.5482/hamo-14-09-0047     Document Type: Review

References (88)

1. Knöfler R, Eberl W, Schulze H et al. Diagnosis of inherited diseases of platelet function. Interdisciplinary s2k guideline of the permanent paediatric committee of the society of thrombosis and haemostasis research (GTH e. V.). Hämostaseologie 2014; 34: 201-212.
2. Jurk K, Kehrel BE. Inherited and acquired disorders of platelet function Transfus Med Hemother 2007; 34: 6-19.
3. Casini A, Fontana P, Lecompte TP. Thrombotic complications of myeloproliferative neoplasms:Risk assessment and risk-guided management. J Thromb Haemost 2013; 11: 1215-1227.
4. Nangalia J, Massie CE, Baxter EJ et al. Somatic calr mutations in myeloproliferative neoplasms with nonmutated jak2. N Engl J Med 2013; 369:2391-2405.
5. Finazzi G, Carobbio A, Thiele J et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 who criteria. Leukemia 2012; 26: 716-719.
6. Balduini CL, Pecci A, Noris P. Inherited thrombocytopenias:The evolving spectrum. Hämostaseologie 2012; 32: 259-270.
7. Nurden AT, Nurden P. Congenital platelet disorders and understanding of platelet function. Br J Haematol 2014; 165: 165-178.
8. Gothwal M, Sandrock-Lang K, Zieger B. Genetics of inherited platelet disorders. Hämostaseologie 2014; 34: 133-141.
9. Gresele P, Harrison P, Bury L et al. Diagnosis of suspected inherited platelet function disorders:Results of a worldwide survey. J Thromb Haemost 2014; 12: 1562-1569.
10. Ozaki Y, Suzuki-Inoue K, Inoue O. Platelet receptors activated via mulitmerization: Glycoprotein vi, gpib-ix-v, and clec-2. J Thromb Haemost 2013; 11 (Suppl 1): 330-339.
11. Jurk K, Clemetson KJ, de Groot PG et al. Thrombospondin-1 mediates platelet adhesion at high shear via glycoprotein ib (gpib): An alternative/ backup mechanism to von Willebrand factor. FASEB J 2003; 17: 1490-1492.
12. Dale GL, Friese P, Batar P et al. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature 2002; 415: 175-179.
13. Offermanns S. Activation of platelet function through g protein-coupled receptors. Circ Res 2006; 99: 1293-1304.
14. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005; 3: 1800-1814.
15. Berndt MC, Andrews RK. Major platelet glycoproteins:Gpib-ix-v. In: Marder VJ, Aird WC, Bennett JS, Schulman S, White II GC (eds). Hemostasis and thrombosis 2012: 382-385.
16. Cosemans JM, Iserbyt BF, Deckmyn H, Heemskerk JW. Multiple ways to switch platelet integrins on and off. J Thromb Haemost 2008; 6:1253-1261.
17. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002; 22: 1381-1389.
18. Varga-Szabo D, Braun A, Nieswandt B. Stim and orai in platelet function. Cell Calcium 2011; 50:270-278.
19. Heemskerk JW, Mattheij NJ, Cosemans JM. Platelet- based coagulation: Different populations, different functions. J Thromb Haemost 2013; 11:2-16.
20. Wielders SJ, Beguin S, Hemker HC, Lindhout T. Factor xi-dependent reciprocal thrombin generation consolidates blood coagulation when tissue factor is not available. Arterioscler Thromb Vasc Biol 2004; 24: 1138-1142.
21. Jurk K, Lahav J, Van Aken H, Brodde MF et al. Extracellular protein disulfide isomerase regulates feedback activation of platelet thrombin generation via modulation of coagulation factor binding. J Thromb Haemost 2011; 9: 2278-2290.
22. Essex DW, Li M. Protein disulphide isomerase mediates platelet aggregation and secretion. Br J Haematol 1999; 104: 448-454.
23. Lahav J, Jurk K, Hess O et al. Sustained integrin ligation involves extracellular free sulfhydryls and enzymatically catalyzed disulfide exchange. Blood 2002; 100: 2472-2478.
24. Bertling A, Niemann S, Hussain M et al. Staphylococcal extracellular adherence protein induces platelet activation by stimulation of thiol isomerases. Arterioscler Thromb Vasc Biol 2012; 32:1979-1990.
25. Thon JN, Peters CG, Machlus KR et al. T granules in human platelets function in tlr9 organization and signaling. J Cell Biol 2012; 198: 561-574.
26. Morrissey JH, Choi SH, Smith SA. Polyphosphate:An ancient molecule that links platelets, coagulation, and inflammation. Blood 2012; 119:5972-5979.
27. Stalker TJ, Traxler EA, Wu J et al. Hierarchical organization in the hemostatic response and its relationship to the platelet-signaling network. Blood 2013; 121: 1875-1885.
28. Brass LF, Wannemacher KM, Ma P, Stalker TJ. Regulating thrombus growth and stability to achieve an optimal response to injury. J Thromb Haemost 2011; 9 (Suppl 1): 66-75.
29. Rondina MT, Weyrich AS, Zimmerman GA. Platelets as cellular effectors of inflammation in vascular diseases. Circ Res 2013; 112: 1506-1519.
30. Koseoglu S, Flaumenhaft R. Advances in platelet granule biology. Curr Opin Hematol 2013; 20:464-471
31. Jurk K, Kehrel BE. Thrombozytensekretion. In:Pötzsch B, Madlener K (eds). Hämostaseologie. Grundlagen, Diagnostik und Therapie 2010:67-72.
32. Duke WW. The relation of blood platelets to hemorrhagic disease. JAMA 1983; 250: 1201-1209.
33. Ivy AC, Nelson D, Buchet C. The standardization of certain factors in the cutaneous 'venostasis' bleeding time technique. J Lab Clin Med 1941; 26:1812.
34. Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990; 16:1-20.
35. Franchini M. The platelet function analyzer (pfa-100): An update on its clinical use. Clin Lab 2005; 51: 367-372.
36. Savion N, Varon D. Impact--the cone and plate(let) analyzer: Testing platelet function and anti-platelet drug response. Pathophysiol Haemost Thromb 2006; 35: 83-88.
37. Michelson AD. Methods for the measurement of platelet function. Am J Cardiol 2009; 103:20A-26A.
38. Bliden KP, DiChiara J, Tantry US et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: Is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007; 49: 657-666.
39. Gurbel PA, Bliden KP, DiChiara J et al. Evaluation of dose-related effects of aspirin on platelet function:Results from the aspirin-induced platelet effect (aspect) study. Circulation 2007; 115:3156-3164.
40. Scharbert G, Auer A, Kozek-Langenecker S. Evaluation of the platelet mapping assay on rotational thromboelastometry rotem. Platelets 2009; 20:125-130.
41. Gurbel PA, Becker RC, Mann KG et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007; 50:1822-1834.
42. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929.
43. Cattaneo M, Cerletti C, Harrison P et al. Recommendations for the standardization of light transmission aggregometry: A consensus of the working party from the platelet physiology subcommittee of ssc/isth. J Thromb Haemost 2013; doi:10.1111/jth.12231.
44. Dawood BB, Lowe GC, Lordkipanidze M et al. Evaluation of participants with suspected heritable platelet function disorders including recommendation and validation of a streamlined agonist panel. Blood 2012; 120: 5041-5049.
45. Chanarin I. Platelet function tests. In: Chanarin I (ed). Laboratory haematology. Edinburgh: Churchill Livingstone 1989: 371-399.
46. Mindukshev I, Gambaryan S, Kehrer L et al. Low angle light scattering analysis: A novel quantitative method for functional characterization of human and murine platelet receptors. Clin Chem Lab Med 2012; 50: 1253-1262.
47. Harrison P, Michelson AD. Laboratory markers of platelet activation. In: Marder VJ, Aird WC, Bennett JS et al (eds). Hemostasis and thrombosis. 2012: 829-839.
48. Schwarz UR, Geiger J, Walter U, Eigenthaler M. Flow cytometry analysis of intracellular vasp phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets--definition and detection of ticlopidine/ clopidogrel effects. Thromb Haemost 1999; 82:1145-1152.
49. Kahr WH, Zheng S, Sheth PM et al. Platelets from patients with the quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator. Blood 2001; 98: 257-265.
50. Hemker HC, Giesen P, Al Dieri R et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
51. Reverter JC, Beguin S, Kessels H et al. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7e3 antibody. Potential implications for the effect of c7e3 fab treatment on acute thrombosis and "clinical restenosis". J Clin Invest 1996; 98: 863-874.
52. Hemker HC, Al Dieri R, De Smedt E, Beguin S. Thrombin generation, a function test of the haemostatic- thrombotic system. Thromb Haemost 2006; 96: 553-561.
53. Van der Meijden PE, Feijge MA, Swieringa F et al. Key role of integrin alpha(iib)beta (3) signaling to syk kinase in tissue factor-induced thrombin generation. Cell Mol Life Sci 2012; 69: 3481-3492.
54. Keularts IM, Beguin S, de Zwaan C, Hemker HC. Treatment with a gpiib/iiia antagonist inhibits thrombin generation in platelet rich plasma from patients. Thromb Haemost 1998; 80: 370-371.
55. Vanschoonbeek K, Feijge MA, Van Kampen RJ et al. Initiating and potentiating role of platelets in tissue factor-induced thrombin generation in the presence of plasma: Subject-dependent variation in thrombogram characteristics. J Thromb Haemost 2004; 2: 476-484.
56. Beguin S, Kumar R, Keularts I et al. Fibrin-dependent platelet procoagulant activity requires gpib receptors and von willebrand factor. Blood 1999; 93: 564-570.
57. Cosemans JM, Schols SE, Stefanini L et al. Key role of glycoprotein ib/v/ix and von Willebrand factor in platelet activation-dependent fibrin formation at low shear flow. Blood 2011; 117: 651-660.
58. Dörmann D, Clemetson KJ, Kehrel BE. The gpib thrombin-binding site is essential for thrombin-induced platelet procoagulant activity. Blood 2000; 96: 2469-2478.
59. Beguin S, Keularts I, Al Dieri R et al. Fibrin polymerization is crucial for thrombin generation in platelet-rich plasma in a vwf-gpib-dependent process, defective in Bernard-Soulier syndrome. J Thromb Haemost 2004; 2: 170-176.
60. Faber CG, Lodder J, Kessels F, Troost J. Thrombin generation in platelet-rich plasma as a tool for the detection of hypercoagulability in young stroke patients. Pathophysiol Haemost Thromb 2003; 33:52-58.
61. Razmara M, Hjemdahl P, Ostenson CG, Li N. Platelet hyperprocoagulant activity in type 2 diabetes mellitus: Attenuation by glycoprotein iib/iiia inhibition. J Thromb Haemost 2008; 6: 2186-2192.
62. Mobarrez F, He S, Broijersen A et al. Atorvastatin reduces thrombin generation and expression of tissue factor, p-selectin and gpiiia on platelet-derived microparticles in patients with peripheral arterial occlusive disease. Thromb Haemost 2011; 106: 344-352.
63. Subcommittee on Control of Anticoagulation of the SSCotI. Towards a recommendation for the standardization of the measurement of platelet-dependent thrombin generation. J Thromb Haemost 2011; 9: 1859-1861.
64. Ninivaggi M, Apitz-Castro R, Dargaud Y et al. Whole-blood thrombin generation monitored with a calibrated automated thrombogram-based assay. Clin Chem 2012; 58: 1252-1259.
65. Sibbing D, Spannagl M. Direct oral anticoagulants and antiplatelet agents. Clinical relevance and options for laboratory testing. Hämostaseologie 2014; 34: 78-84.
66. Schubert S, Weyrich AS, Rowley JW. A tour through the transcriptional landscape of platelets. Blood 2014; 124: 493-502.
67. Jurk K, Kehrel BE. Pathophysiology and biochemistry of platelets. Internist (Berl) 2010; 51: 1086, 1088-1092, 1094.
68. Van Kruchten R, Cosemans JM, Heemskerk JW. Measurement of whole blood thrombus formation using parallel-plate flow chambers - a practical guide. Platelets 2012; 23: 229-242.
69. Colace TV, Tormoen GW, McCarty OJ, Diamond SL. Microfluidics and coagulation biology. Annu Rev Biomed Eng 2013; 15: 283-303.
70. Roest M, Reininger A, Zwaginga JJ et al. Flow chamber-based assays to measure thrombus formation in vitro: Requirements for standardization. J Thromb Haemost 2011; 9: 2322-2324.
71. Zwaginga JJ, Sakariassen KS, King MR et al. Can blood flow assays help to identify clinically relevant differences in von willebrand factor functionality in von willebrand disease types 1-3? J Thromb Haemost 2007; 5: 2547-2549.
72. Brehm MA, Huck V, Aponte-Santamaria C et al. Von Willebrand disease type 2a phenotypes iic, iid and iie: A day in the life of shear-stressed mutant von Willebrand factor. Thromb Haemost 2014; 112: 96-108.
73. De Witt SM, Swieringa F, Cavill R et al. Identification of platelet function defects by multi-parameter assessment of thrombus formation. Nat Commun 2014; 5: 4257.
74. Cadroy Y, Bossavy JP, Thalamas C et al. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation 2000; 101: 2823-2828.
75. Mendolicchio GL, Zavalloni D, Bacci M, Corrada E, Marconi M, Lodigiani C, Presbitero P, Rota L, Ruggeri ZM. Variable effect of p2y12 inhibition on platelet thrombus volume in flowing blood. J Thromb Haemost 2011; 9:373-382.
76. Di Michele M, Van Geet C, Freson K. Recent advances in platelet proteomics. Expert Rev Proteomics 2012; 9: 451-466.
77. Senis Y, Garcia A. Platelet proteomics: State of the art and future perspective. Methods Mol Biol 2012; 788: 367-399.
78. Burkhart JM, Gambaryan S, Watson SP et al. What can proteomics tell us about platelets? Circ Res 2014; 114: 1204-1219.
79. Burkhart JM, Vaudel M, Gambaryan S et al. The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways. Blood 2012; 120: e73-82.
80. Beck F, Geiger J, Gambaryan S et al. Time-resolved characterization of camp/pka-dependent signaling reveals that platelet inhibition is a concerted process involving multiple signaling pathways. Blood 2014; 123: e1-e10.
81. Quiroga T, Goycoolea M, Munoz B et al. Template bleeding time and pfa-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: Comparative study in 148 patients. J Thromb Haemost 2004; 2: 892-898.
82. Sladky JL, Klima J, Grooms L et al. The pfa-100 (r) does not predict delta-granule platelet storage pool deficiencies. Haemophilia 2012; 18: 626-629.
83. Favaloro EJ, Koutts J. 2b or not 2b? Masquerading as von Willebrand disease? J Thromb Haemost 2012; 10: 317-319.
84. Gordon N, Thom J, Cole C, Baker R. Rapid detection of hereditary and acquired platelet storage pool deficiency by flow cytometry. Br J Haematol 1995; 89: 117-123.
85. Linden MD, Frelinger AL 3rd, Barnard MR et al. Application of flow cytometry to platelet disorders. Semin Thromb Hemost 2004; 30: 501-511.
86. Gunay-Aygun M, Zivony-Elboum Y, Gumruk F et al. Gray platelet syndrome: Natural history of a large patient cohort and locus assignment to chromosome 3p. Blood 2010; 116: 4990-5001.
87. Jurk K, Schulz AS, Kehrel BE et al. Novel integrindependent platelet malfunction in siblings with leukocyte adhesion deficiency-iii (lad-iii) caused by a point mutation in fermt3. Thromb Haemost 2010; 103: 1053-1064.
88. Dovlatova N, Lordkipanidze M, Lowe GC et al. Evaluation of a whole blood remote platelet function test for the diagnosis of mild bleeding disorders. J Thromb Haemost 2014; 12: 660-665.